Deschatelets Pascal's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Mar 11, 2024
- Accession no.
- 0001127602-24-009368
- Filed
- Mar 11, 2024
- Trade date
- Mar 8, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.30M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deschatelets PascalCIK 0001657720 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2024 | Common Stock | MOption exerciseAcquired | +69,107 | $3.67 | +$253,622.69 | 1,185,090 | Direct | |
| Mar 8, 2024 | Common Stock | SSaleDisposed | −42,750 | $61.88 | −$2,645,370 | 1,142,340 | Direct | |
| Mar 8, 2024 | Common Stock | SSaleDisposed | −26,257 | $62.69 | −$1,646,051.33 | 1,116,083 | Direct | |
| Mar 8, 2024 | Common Stock | SSaleDisposed | −100 | $63.35 | −$6,335 | 1,115,983 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2024 | Common Stock | MOption exerciseDisposed | −69,107 | $0.00 | $0 | 106,387 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.